Evidence map›Paper›PMID 42879016›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2027

Proliferation Assessment by Trypan Blue Exclusion in Ewing Sarcoma.

Christine Sauerteig, Zara Michels, Moritz Kuehnle, Cornelius M Funk, Julian Musa

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christine SauerteigDepartment of General, Visceral, and Transplant Surgery, University Hospital of Heidelberg, Heidelberg, Germany.
Zara MichelsDepartment of General, Visceral, Thoracic, and Transplant Surgery, University Hospital of Giessen and Marburg, Giessen, Germany.
Moritz KuehnleDepartment of General, Visceral, Thoracic, and Transplant Surgery, University Hospital of Giessen and Marburg, Giessen, Germany.
Cornelius M FunkDepartment of Hematology, Oncology, and Rheumatology, University Hospital of Heidelberg, Heidelberg, Germany.
Julian MusaDepartment of General, Visceral, Thoracic, and Transplant Surgery, University Hospital of Giessen and Marburg, Giessen, Germany. Julian.Musa@chiru.med.uni-giessen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell proliferation is broadly defined as the process that increases cell number, essentially depending on a balance among cell cycle progression, cell division, cell death, and cellular senescence. Deregulation of cell proliferation is a key feature of cancer cells, making assessment of proliferation a central methodological issue in cancer research. Especially in Ewing sarcoma (EwS), which exhibits a high proliferative capacity, experimental assessment of proliferation in preclinical research plays an important role. Among the available methods, Trypan blue exclusion is described here as a robust, easy-to-perform, and cost-effective method for assessing cell proliferation in an experimental setting.

Indexed as

Cell ProliferationSarcoma, EwingTrypan BlueCell Line, TumorCellular SenescenceHumansStaining and LabelingTrypan BlueCell deathCell divisionEwing sarcomaProliferationSenescenceTrypan blue

Identifiers

PMID42879016

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.